Drug recall · January 17, 2018
Moexipril Hydrochloride and Hydrocholorothiazide Tablets USP recall
Why: Failed Impurities/Degradation Specifications: High out of specification test result for the Moexipril Diketopiperazine impurity was obtained during routine stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Moexipril Hydrochloride and Hydrocholorothiazide Tablets USP, 7.5 mg/12.5 mg, 100-count bottle, Rx only, Distributed By: TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5213-01.
- Lots / codes
Lot # 30229439A, Exp 12/17
- Quantity
- 4,969 bottles
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Nationwide in the USA
- Initiated
- December 14, 2017 · Voluntary: Firm initiated
- Classified
- January 8, 2018
- Reported
- January 17, 2018
- Ended
- October 1, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Moexipril
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.